
<img src="https://www.gustaveroussy.fr/sites/all/themes/gustave_roussy/logo.png" alt="logo GR">
<img src="https://www.inserm.fr/themes/inserm/logo.png" alt="logo INSERM" width="200px">
<img src="https://www.ligue-cancer.net/sites/all/themes/ligue/logo.png" alt="logo LCC">
<img src="https://hal.archives-ouvertes.fr/UNIV-PARIS-SACLAY/public/logo_UP_saclay_final.png" alt="logo UPSC" width="150px">

Oncostat is a research team of the Centre for Epidemiology and Population Health (CESP). More information on  [https://cesp.inserm.fr/en/equipe/oncostat](https://cesp.inserm.fr/en/equipe/oncostat).

## Teaching

 + [R Notebooks](https://github.com/Oncostat/R_notebooks)
 + INSERM workshop 2017: predictionPenalized [[link](https://github.com/Oncostat/predictionPenalized)]
 + Book: Textbook of Clinical Trials in Oncology: A Statistical Perspective [[link]( https://www.routledge.com/Textbook-of-Clinical-Trials-in-Oncology-A-Statistical-Perspective/Halabi-Michiels/p/book/9781138083776) and [supplemental material](https://www.routledge.com/downloads/K34556/stat%20code%20book%20halabi%20michiels.zip)]


## Software

### R packages and code

 + Biomarker selection in penalized regression models, package `biospear` [![CRAN_Status_Badge](https://www.r-pkg.org/badges/version/biospear)](https://cran.r-project.org/package=biospear) [[link](https://github.com/Oncostat/biospear)]
   + *Described in*: Nils Ternès, Federico Rotolo, Stefan Michiels, biospear: an R package for biomarker selection in penalized Cox regression, Bioinformatics, Volume 34, Issue 1, 01 January 2018, Pages 112–113, https://doi.org/10.1093/bioinformatics/btx560
 + Evaluation of Failure Time Surrogate Endpoints in Individual Patient Data Meta-Analyses, package `surrosurv` [![CRAN_Status_Badge](https://www.r-pkg.org/badges/version/surrosurv)](https://cran.r-project.org/package=surrosurv) [[link](https://github.com/Oncostat/surrosurv)]
   + *Described in*: Federico Rotolo, Xavier Paoletti, Stefan Michiels, surrosurv: an R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials https://doi.org/10.1016/j.cmpb.2017.12.005
 + Parametric Frailty Models, package `parfm` [![CRAN_Status_Badge](https://www.r-pkg.org/badges/version/parfm)](https://cran.r-project.org/package=parfm) [[link](https://github.com/Oncostat/parfm)]
 + Group-sequential-adaptive-designs-in-series-of-time-to-event-randomized-trials-in-rare-diseases [[link](https://github.com/Oncostat/Group-sequential-adaptive-designs-in-series-of-time-to-event-randomized-trials-in-rare-diseases)]
 + Mixed Effect Multivariate Continuation Ratio model [[link](https://github.com/Oncostat/POP1)]
 + Estimation of the probability of patients having a time to progression ratio superior to a given threshold [[link](https://github.com/Oncostat/TTPratio)]
 
#### Under development 

 + Drop the losers with historical control group [[link](https://github.com/Oncostat/DTLHC)]

 
### SAS macros
 + Dual-Agent Bayesian Continual Reassessment Method [[link](https://github.com/Oncostat/CRM2dim)]

### Others
 + BenchmarkNCVTools [[link](https://github.com/Oncostat/BenchmarkNCVTools)]

## Supplementary Material of Publication

 + PrognosTILs application [[link](https://github.com/Oncostat/PrognosTILs)]
 + Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: What methods are used in practice? Clinical Trials. 2017; 14(1):78-87 [Supplementary material (Excel table)](https://www.gustaveroussy.fr/sites/default/files/article_ct-16-0032-r1_supplementary_material.xlsx)
 
## Other

 + ...
